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Dear Editor, 
with this letter we would like to describe the most recent evidences highlighting the role of 
autoimmunity in Huntington’s Disease (HD) pathogenesis. 
Huntington’s disease (HD) is a inherited neurodegenerative disorder characterized by marked 
psychiatric, cognitive and motor impairments. The features of the disease are caused by a CAG 
codon/polyglutamine repeat expansion in the huntingtin gene, which leads to the expression of a 
mutated form of the huntingtin protein (mHtt) in cells of the central nervous system [1]. There is 
now emerging data providing compelling evidence for immune abnormalities in HD, which are 
central to the disease process.  
At the cellular level, neuronal dysfunction has been proposed to be mediated by intermediate stages 
of polyglutamine aggregates [1] which lead to cytoplasmic and nuclear inclusions of aggregated 
mHtt that are already present at the onset of the disease . The specific mechanisms linking the 
abnormally expanded huntingtin with the pathogenesis of HD are not well understood, but 
experimental data suggest that excitotoxicity, metabolic impairment and oxidative stress are all 
involved in the neurodegenerative process [1].  The recent development of a transgenic mouse in 
which astrocytes were engineered to express the mHtt, has demonstrated that expressing the mutant 
protein only in this cell type can drive neurological impairments. The question on the specific role 
of astrocytes in immunity and HD needs to be addressed. In pathological conditions, astrocytes can 
be activated to produce cytokines, but are unlikely to behave as efficient antigen-presenting cells, 
because the upregulation of major histocompatibility complex class II molecules on this cell type is 
a rare event [2].  
mHtt has been reported in monocytes, microglia and astrocytes of HD patients [3], but the detection 
of mHtt expression in cell populations outside the CNS has received only limited attention, with a 
single report describing nuclear inclusions in the postmortem muscle tissue of a HD patient [4]. 
Interestingly, there is increased complement biosynthesis (for example, C3 and C9) by microglia in 
the brains of HD patients, and so it has been proposed that the complement system is activated in 
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the membranes of neurons, thus inducing cytotoxicity, which may in turn contribute to neuronal 
death [5]. The IkB kinase/nuclear factor-kB signaling pathway that triggers IL-6 release is also 
upregulated by mHtt, potentially participating in neurotoxicity [6].  
The correlation of mHtt and disease expression in various systems, originating in peripheral tissues, 
is proving very interesting and intriguing. Indeed it can be surmised that the soluble or aggregated 
forms of mHtt are released on neuronal cell death, and subsequently detected and captured by 
immune cells as immunogenic molecules. Misfolded mHtt could be sensed as an ‘‘infectious’’ 
protein triggering an immune response in much the same way as other proteins–for example, 
extracellular amyloid can be taken up by macrophages through a phagocytic or receptor-mediated 
endocytic process [7]. Remarkably, synthetic polyQ peptides can also be ingested by cells in 
culture, which can then translocate to the nucleus where they become cytotoxic [8]. Moreover, 
internalized fibrillar aggregates are able to interact with soluble cytoplasmic proteins [9]. 
Two hypotheses emerge from these concepts: the release of immunogenic molecules from dying 
neurons could trigger an immune response, or sensitize the immune cells to the inflammatory 
environment. Alternatively, the intrinsic microglial expression of the mHtt might compromise their 
physiological function and exacerbate the release of pro-inflammatory cytokines, quinolinic acid 
(QA) and oxygen species.. 
There is therefore accumulating evidence that the immune system is activated in HD, and two 
consequent mechanisms could be proposed to account for this. In the first instance, the altered 
immune profiles as detected in pre-symtomatic HD patients would suggest that immune activation 
takes place before neuronal degeneration. In an alternative scenario, the expression of mHtt could 
sensitize immune cells to overreact toward degenerating neurons.  
Dissecting the contribution of the immune response to HD pathology, and fully understanding 
whether this phenomenon is a cause or a consequence of the disease, is still not clear.  
 
 
4	  
	  
References 
[1] Mukai H, Isagawa T, Goyama E, Tanaka S, Bence NF, Tamura A et al. Formation of  
[2] Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in 
mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 
2009; 106:22480-22485 
[3] Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S et al. Mutant huntingtin in glial cells 
exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 2010; 285: 10653-
10661 
[4] Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B et al. Mitochondrial 
impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov Disord 
2005; 20: 674-679 
[5] Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia 
and complement activation on neurons in Huntington’s disease. Exp Neurol 1999; 159: 362-376 
[6] Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the 
IkappaB kinase complex and nuclear factorkappaB contributes to mutant huntingtin neurotoxicity. J 
Neurosci 2004; 24: 7999-8008 
[7] Morten IJ, Gosal WS, Radford SE, Hewitt EW. Investigation into the role of macrophages in the 
formation and degradation of beta2-microglobulin amyloid fibrils. J Biol Chem 2007; 282: 29691-
29700 
[8] Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides delivered to 
nuclei are toxic to mammalian cells. Hum Mol Genet 2002; 11: 2905-2917 
[9] Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration 
and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009;11: 
219-225 
 
